This is a India news story, published by Yahoo, that relates primarily to Novo Nordisk's news.
For more India news, you can click here:
more India newsFor more Novo Nordisk's news, you can click here:
more Novo Nordisk's newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
popular obesity drug Wegovy. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Pharmaceuticals news, loss drugs market news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Danish drugmaker Novo NordiskReuters
•78% Informative
GLP-1 drugs, originally approved to treat diabetes, are widely being used to treat obesity.
Danish drugmaker Novo Nordisk's patent on semaglutide is set to expire in India in 2026.
Drugmakers across the globe are looking to grab a slice of the weight-loss drugs market.
VR Score
89
Informative language
97
Neutral language
39
Article tone
formal
Language
English
Language complexity
64
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links